Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs

The recently conducted ADAURA trial concludes daily dosing of adjuvant osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), improves disease-free survival with stage IB/II/IIIA EGFR -mutated non-small cell lung cancer patients in comparison to placebo. We have developed a preclinica...

Полное описание

Библиографические подробности

Главные авторы:	Ashwin Butle, Asim Joshi, Vanita Noronha, Kumar Prabhash, Amit Dutt
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2021-08-01
Серии:	Translational Oncology
Предметы:	ADAURA trial Adjuvant EGFR-TKI treatment Orthotopic mouse lung cancer model Tail vein injection Bioluminescence imaging
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S1936523321001030
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!